Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON , Canada.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2178217. doi: 10.1080/21645515.2023.2178217. Epub 2023 Feb 12.
Adjuvant and neoadjuvant therapies that reduce the risk of renal cell carcinoma (RCC) recurrence remain an area of unmet need. Advances have been made in metastatic RCC recently by leveraging PD-1/PD-L1 immune checkpoint inhibitors (ICIs). These agents are currently being investigated in the adjuvant and neoadjuvant settings to determine if intervention early in the disease trajectory offers a clinically meaningful benefit. While a disease-free survival benefit has been demonstrated with pembrolizumab, results from other ICI studies have not been positive to date. More mature data from these studies are needed to determine whether there is a survival benefit to ICIs in the curative-intent setting. The success of ICIs has also ushered a new wave of studies combining ICIs with other agents such as targeted therapies and vaccines, which are in early stages of investigation. We review the current state of adjuvant/neoadjuvant therapy in RCC and highlight opportunities for ongoing study.
辅助和新辅助治疗可降低肾细胞癌（RCC）复发的风险，但仍存在未满足的需求。最近，通过利用 PD-1/PD-L1 免疫检查点抑制剂（ICI），转移性 RCC 取得了进展。这些药物目前正在辅助和新辅助治疗中进行研究，以确定疾病早期干预是否具有临床意义的益处。虽然 pembrolizumab 已显示出无疾病生存获益，但迄今为止，其他 ICI 研究的结果并非阳性。需要从这些研究中获得更成熟的数据，以确定在治愈性治疗中 ICI 是否具有生存获益。ICI 的成功还迎来了一波新的研究，将 ICI 与其他药物（如靶向治疗和疫苗）联合使用，这些药物仍处于早期研究阶段。我们回顾了 RCC 辅助/新辅助治疗的现状，并强调了正在进行的研究机会。
